The infectious disease therapeutics market size in 2022 stood at US$ 1,19,708.77 million and is projected to reach US$ 1,67,883.93 million by 2030. The market is expected to register a CAGR of 4.30% during 2022–2030. Rising number of product approvals and launches is likely to remain key trends in the market.
The rising prevalence of infectious diseases in society, the market players have released advanced medicines for the treatment of infectious disorders, the initiatives taken by the government to provide individuals with sophisticated facilities for the treatment of infectious diseases is driving the market.
Bacteria, viruses, fungus, and parasites are all creatures that cause infectious diseases. Antibiotics, antivirals, and antiparasitics are some of the medications used to treat infectious disorders. Therapeutics for infectious diseases could act directly on organisms or aid the body's immune system in fighting infections. Infectious diseases include HIV, tuberculosis, malaria, hepatitis, and influenza, among others.
Research and development (R&D) is a important part of the business of pharmaceutical companies and biopharmaceuticals. R&D allows the companies to launch new products for several therapeutic applications with significant medical and commercial potential. Also, leading market players are investing in R&D to develop enhanced technologies and gain more revenue share.
The table below displays the annual funding for various disease categories and research on the basis of contracts, grants, and other funding mechanisms used across the National Institutes of Health (NIH).
Emerging Infectious Diseases
2,950
4,867
5,069
4,318
Infectious Diseases
6,313
8,301
8,599
8,019
Sexually Transmitted Infections
354
394
404
419
Note: Current conversion rate is considered for the currencies.
Source: Annual Reports and The Insight Partners Analysis
The major projects that the manufacturers have funded:
• In June 2022, GSK plc invested US$ 1.21 billion (£1 billion) over 10 years to expedite research and development (R&D) focused on infectious diseases that disproportionately affect low-income nations. The research will concentrate on new medicines and disruptive vaccines to prevent and treat malaria, tuberculosis, HIV (via ViiV Healthcare), neglected tropical diseases (NTDs), and anti-microbial resistance (AMR).
• In March 2022, the Global Fund's COVID-19 Response Mechanism (C19RM) received a donation of US$ 48.07 million (CAD 60 million) from Canada which was praised by the Global Fund to Fight AIDS, Tuberculosis, and Malaria. The new funds was used to offer low- and middle-income countries with vital treatments and diagnostic tests, including medical oxygen, and personal protective equipment (PPE).
Thus, rising focus on R&D and funding is driving the infectious disease therapeutics market growth.
The rising prevalence of infectious diseases is anticipated to improve sales of infectious disease treatment medications in emerging countries. Because of the lower data requirements and stricter laws, Asia Pacific has emerged as a flexible and business-friendly region. Furthermore, large investments in health research and life science in emerging countries play an important role in supporting cutting-edge technology in developing countries, which in turn encourages the trend towards infectious disease detection and treatment. For example, UNAIDS is calling for a US$ 29 billion investment by 2025 to satisfy the AIDS prevention and treatment needs of low- and middle-income countries. In India, South Korea, Brazil, and Mexico, infectious diseases such as Hepatitis, HAI, HIV, and influenza are prevalent; there is a big patient population; disposable money has increased; healthcare infrastructure has improved; and medical tourism is expanding. Thus, essential infectious disease therapeutics product producers in expanding infectious disease therapeutics markets in these nations should expect profitable prospects in the future.
Key segments that contributed to the derivation of the infectious disease therapeutics market analysis are drug class, indication, route of administration, distribution channel.
The geographic scope of the infectious disease therapeutics market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.
North America has dominated the market. Growing adoption of technological advancements and rising research and development activities are projected to accelerate the growth of the infectious disease therapeutics market. Moreover, large healthcare businesses and the rising demand for advanced therapeutic solutions to treat chronic conditions and viral diseases are propelling the market expansion in this region.
The regional trends and factors influencing the Infectious Disease Therapeutics Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Infectious Disease Therapeutics Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 1,19,708.77 Million |
| Market Size by 2030 | US$ 1,67,883.93 Million |
| Global CAGR (2022 - 2030) | 4.3% |
| Historical Data | 2020-2021 |
| Forecast period | 2022-2030 |
| Segments Covered |
By Drug Class
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Infectious Disease Therapeutics Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Infectious Disease Therapeutics Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The infectious disease therapeutics market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the infectious disease therapeutics market are listed below:
The “Infectious Disease Therapeutics Market Size and Forecast (2020–2030)” report provides a detailed analysis of the market covering below areas:
The market is estimated to grow at a CAGR of 4.5% during 2023–2031.
Rising prevalence of infectious disease and increasing focus on funding and R&D for infectious disease therapeutics are the factors driving the market.
The estimated value of the market by 2031 will be US$ 176.17 billion.
Rising number of product approvals and launches is likely to act as future trends in the market.
Pfizer Inc, Gilead Sciences Inc, F. Hoffmann-La Roche Ltd, Shionogi & Co Ltd, Bayer AG, BioCryst Pharmaceuticals Inc, GSK Plc, AbbVie Inc, Merck & Co Inc, and Astellas Pharma Inc are the leading players operating in the infectious diasease therapeutics market.
North America dominated the market in 2023.